Therapeutic Classification: antianginals, antihypertensives
Pharmacologic Classification: calcium channel blockers
Unlabeled Use:
Absorption: Well absorbed after oral administration, but large amounts are rapidly metabolized, resulting in ↓ bioavailability (45–70%); bioavailability is ↑ (80%) with extended-release forms.
Distribution: Unknown.
Protein Binding: 92–98%.
Metabolism/Excretion: Mostly metabolized by the liver by the CYP3A4 isoenzyme.
Half-life: 2–5 hr.
Contraindicated in:
Use Cautiously in:
CV: peripheral edema, bradycardia, chest pain, HF, hypotension, palpitations, syncope, tachycardia.
Derm: flushing, ↑ sweating, dermatitis, erythema multiforme, photosensitivity, pruritus/urticaria, rash, STEVENS-JOHNSON SYNDROME.
EENT: blurred vision, disturbed equilibrium, epistaxis, tinnitus.
Endo: gynecomastia, hyperglycemia.
GI: ↑liver enzymes, GI obstruction, anorexia, constipation, diarrhea, dry mouth, dyspepsia, nausea, vomiting.
GU: dysuria, nocturia, polyuria, sexual dysfunction, urinary frequency.
Hemat: anemia, leukopenia, thrombocytopenia.
Metab: weight gain.
MS: joint stiffness, muscle cramps.
Neuro: paresthesia, tremor.
Resp: cough, dyspnea, shortness of breath.
Misc: gingival hyperplasia.
Drug-Drug:
Drug-Natural Products:
Drug-Food:
Adalat CC, Afeditab CR, Procardia, Procardia XL
NDC Code*